Product name
Novel Ibuprofen derivatization method with improved pharmacologySummary
One step synthesis, easy derivatisation and improved absorption.Organization name
ipal GmbHProfile
Ibuprofen is a non-steroidal anti-inflammatory drug widely prescribed for its analgesic and antipyretic activity. Over the years the original Ibuprofen has been modified to further improve the properties such as water solubility in form of a lysine salt.
Researchers at the Freie Univesität Berlin have developed a novel approach to a Ibuprofen derivative.
Advantages
- One step, convenient synthesis
- Substance is expected to have anti-inflammatory activity comparable to that of Ibuprofen with improved pharmacological properties
- Substance is expected to show improved body absorption
- Possibly smaller daily dose required
- Substance could be easily modified (esters, salts etc) to tailor properties
An EP patent application was filed.
Additional information is provided in the attached pdf. The novel Ibuprofen derivative was developed at Freie Universität Berlin and is offered by IPAL.
Contact
Dr. Andreas Voigt
andreas.voigt(at)ipal.de
About IPAL
The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.
Description File
07041_Ibuprofen_Derivative.pdf
print this page
